Resona Asset Management Co. Ltd. Acquires Shares of 27,985 STERIS plc $STE

Resona Asset Management Co. Ltd. bought a new position in shares of STERIS plc (NYSE:STE) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 27,985 shares of the medical equipment provider’s stock, valued at approximately $6,723,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in STE. Fullcircle Wealth LLC boosted its stake in STERIS by 6.7% during the 2nd quarter. Fullcircle Wealth LLC now owns 1,112 shares of the medical equipment provider’s stock valued at $254,000 after purchasing an additional 70 shares during the last quarter. Machina Capital S.A.S. bought a new position in shares of STERIS in the second quarter valued at approximately $460,000. State of Michigan Retirement System lifted its holdings in shares of STERIS by 0.4% in the second quarter. State of Michigan Retirement System now owns 26,748 shares of the medical equipment provider’s stock valued at $6,425,000 after purchasing an additional 100 shares in the last quarter. Aurdan Capital Management LLC purchased a new position in shares of STERIS during the second quarter valued at approximately $901,000. Finally, iA Global Asset Management Inc. grew its holdings in STERIS by 13.8% during the second quarter. iA Global Asset Management Inc. now owns 6,530 shares of the medical equipment provider’s stock worth $1,569,000 after buying an additional 791 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Transactions at STERIS

In other news, VP Renato Tamaro sold 3,204 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $249.24, for a total value of $798,564.96. Following the sale, the vice president owned 7,221 shares of the company’s stock, valued at $1,799,762.04. The trade was a 30.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Daniel A. Carestio sold 159 shares of the business’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $241.82, for a total transaction of $38,449.38. Following the sale, the chief executive officer directly owned 51,096 shares in the company, valued at $12,356,034.72. The trade was a 0.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.07% of the company’s stock.

STERIS Trading Up 1.5%

NYSE:STE opened at $263.88 on Monday. The firm’s 50 day moving average is $243.98 and its 200 day moving average is $239.10. STERIS plc has a 12 month low of $200.98 and a 12 month high of $265.56. The stock has a market capitalization of $25.99 billion, a PE ratio of 40.41 and a beta of 1.02. The company has a current ratio of 2.22, a quick ratio of 1.53 and a debt-to-equity ratio of 0.27.

STERIS (NYSE:STE) last released its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a return on equity of 14.17% and a net margin of 11.61%.During the same period last year, the business posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Sell-side analysts expect that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Tuesday, November 18th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Tuesday, November 18th. STERIS’s payout ratio is currently 36.21%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Morgan Stanley raised their price target on shares of STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Finally, KeyCorp upped their price objective on shares of STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 22nd. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $273.50.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.